Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

were randomized on a 1:1 ratio to either Vidaza of the CCR with stratification by FAB subtypes (RAEB or RAEB-T) and IPSS subgroups (INT-2 or HIGH). Investigators selected the CCR option for each individual patient prior to randomization. The primary objective of the trial was to demonstrate superiority in survival of Vidaza plus best supportive care versus CCR plus best supportive care in higher-risk MDS patients. Secondary objectives of the trial included transfusion independence, hematologic status, hematologic response and hematologic improvement, episodes of infections requiring intravenous antibiotics, time to relapse after complete response (CR) or partial response (PR), time to disease progression, time to transformation to AML, time to transformation or death from any cause, safety and toxicity and pharmacoeconomics.

About Vidaza

In May 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza, the first in a new class of drugs called demethylation agents, for treatment of all five MDS subtypes, which include both low-risk and high-risk patients. These subtypes include: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of Vidaza required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of Vidaza cause the death of rapidly dividing cells,
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

3

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Chief Executive Officer of Neurocrine Biosciences, will be presenting at ... Conference in Boston.   The live presentation takes ... / 8:20 a.m. Pacific Time.  The presentation will be webcast ... http://www.neurocrine.com . If you are unable to ...
(Date:5/23/2013)... 23, 2013 Nephros, Inc. (OTC Bulletin Board: ... company that develops and sells high performance liquid purification ... offering.  In addition, the concurrent temporary reduction in exercise ... May 17, 2013. Nephros estimates that it ... rights offering.   A portion of the proceeds will be ...
(Date:5/23/2013)... May 23, 2013  A recently published clinical study ... Houston, Texas , demonstrates that 3D mammography (breast ... detection. The study, "Implementation of Breast ... was led by Stephen L. Rose ... the American Journal of Roentgenology (AJR). The ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
... POH, AIM: PSG, OTCQX: PPGNY) today announced that, ... Phase 1 transdermal,oxycodone clinical trial aimed at providing ... Phosphagenics has submitted all necessary documents for ... at CMAX - an independent clinical research,organization located ...
... First internal candidate to enter Phase 2 clinical ... PCOP ), an innovator in the discovery ... the initiation of a Phase 2a,clinical study of ... a dual-acting angiotensin and endothelin receptor antagonist,(DARA) that ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
(Date:5/24/2013)... 24 (HealthDay News) -- New research suggests a ... people with insomnia. Every additional hour someone ... percent drop in the likelihood of moderate or ... the University of Pennsylvania. "We were ... sleep duration and suicide risk," study author, Linden ...
(Date:5/24/2013)... commonly used to treat glaucoma may cause droopy eyelids ... according to a new study. The drugs, known ... eye pressure, have already been shown to cause blurred ... said, suggesting that the new findings could lead to ... conservative when prescribing these drugs, the researchers added, particularly ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Area homeowners dreaming ... of new hot tubs to choose from at factory-direct pricing ... . The sales event takes place at Emerald Pool ... 2013. , Jacuzzi, the industry's leading hot tub brand, ... across the country. The event will feature popular hot tub ...
(Date:5/24/2013)... mutations central to the development of infantile myofibromatosis (IM)a ... and soft tissuemay provide new therapeutic targets, according to ... Sinai. The findings, published in the American Journal ... options for this debilitating disease, for which the only ... tumors. , IM is an inheritied disorder that develops ...
(Date:5/24/2013)... (HealthDay News) -- People with high levels of cadmium ... of liver disease than those with lower levels, a ... in urine is evidence of long-term exposure to the ... tobacco smoke, the Johns Hopkins researchers explained. They ... directly causes liver disease but instead suggest an association ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2
... Jan. 13 Genomma Lab Internacional,S.A.B. de C.V. (BMV: ... the main preliminary indicators obtained at the close of ... slightly lower results than the,original growth expectations. However, product ... line with original projections. , ...
... welcomes Los Angeles Mayor Antonio Villaraigosa, Cal State ... representatives and other dignitaries for the construction dedication ... 13 Today, Grifols SA (Grifols), a global ... Los Angeles Mayor Antonio Villaraigosa., Cal State LA ...
... WASHINGTON, Jan. 13 Speaker Nancy Pelosi released ... bipartisan legislation to expand the State Children,s Health ... Similar bipartisan legislation was vetoed twice by President ... bill, click here http://www.speaker.gov/newsroom/legislation?id=0270: "Today, the House ...
... The following was released today by the Office of the ... , On Wednesday, ... Health Insurance Program (SCHIP) Reauthorization bill. This bipartisan bill ... 11 million children -- preserving coverage for the 7 ...
... SRA International, Inc. (NYSE: SRX ), ... and solutions to government organizations and commercial clients, will ... release after close of market on Thursday, Feb. 5, ... call beginning at 5 p.m. EST.Interested parties may listen ...
... helped with pain, fatigue and depression, study shows ... may help people living with the chronic pain ... quality of life, new research shows. , The ... Saarbrucken in Germany, found that fibromyalgia patients had ...
Cached Medicine News:Health News:Grifols Celebrates Initial Construction of New IVIG Facility with Los Angeles Officials and Dignitaries 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 3Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 4Health News:SRA Schedules Second Quarter Fiscal Year 2009 Earnings Release and Conference Call 2
... Aegis CheckPoint is an automated, ... logging and alert system for refrigerator, ... replace chart recorders, data loggers and ... installs on an existing PC and ...
... as three tests confirmed Sterillium Rub's extremely ... to FDA (Time Kill study and Tentative ... Products) and one European test - with ... relevant international efficacy specifications. Sterillium Rub with ...
Chlorhexidine Gluconate, exceptionally persistent and broad spectrum antimicrobial properties have led to its recognition as the most effective agent available for surgical scrubbing, hand washing, p...
Amino+Derm moisturizers and soaps are specifically engineered to aid in the prevention of skin irritations and to help maintain healthy, intact skin....
Medicine Products: